Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 3, 2009, Pages 238-239

  Abe, Masanori ^a   Kikuchi, Fumito ^b   Okada, Kazuyoshi ^a   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yamato Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ABSENCE OF SIDE EFFECTS; ANURIA; BLOOD SAMPLING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG METABOLISM; HALF LIFE TIME; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; RENAL DIALYSIS; THIAZOLIDINEDIONES;

EID: 66549088735     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00694.x     Document Type: Letter

References (8)

1. Ciraldi TP, Huber-Knudsen K, Hickman M, Olefsky J. Regulation of glucose transport in culture muscle cells by novel hypoglycemic agents. Metabolism 1995 44 : 976 82.
2. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998 47 : 507 14.
3. Cox PJ, Ryan DA, Hollis FJ et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000 28 : 772 80.
4. Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000 54 : 333 7.
5. Thompson CK, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end stage renal disease. J Int Med Res 2002 30 : 391 9.
6. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003 55 : 368 74.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 71.
8. Dormandy JA, Charbonnel B, Eckland D et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 2005 366 : 1279 89.